Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
MedPlus Health Services Limited informed exchanges that its subsidiary Optival Health Solutions Private Limited received a drug license suspension order from the Assistant Director, Drugs Control Administration, Madikeri Circle, Karnataka. The suspension applies to one store located at S Rammurthy Road, Virajpet, Karnataka, and is for a period of two days. The order was received on January 10, 2026, and was issued under Rule 65 of the Drugs and Cosmetics Act, 1940. The estimated financial impact is a potential revenue loss of approximately Rs 0.74 lakhs. The company has disclosed the details as required under SEBI Listing Regulations.
This is a minor, routine regulatory matter affecting only a single store for two days, with a negligible revenue impact of under Rs 1 lakh. It is unlikely to have any meaningful effect on the company's overall operations or stock price.